NanoViricides, Inc. Announces Participation in the D. Boral Capital Global Conference
Rhea-AI Summary
NanoViricides (NYSE American: NNVC) will participate in the D. Boral Capital Global Conference on May 7, 2026 at The Plaza Hotel, New York City. Anil R. Diwan, PhD, President & Exec. Chairman, will host one-on-one meetings from 9:45 A.M. to 2:45 P.M. ET.
Interested parties should contact the DBC Conference Team to register for meetings.
Positive
- None.
Negative
- None.
Key Figures
Historical Context
| Date | Event | Sentiment | 24h Move | Catalyst |
|---|---|---|---|---|
| May 04 | Orphan designation | Positive | +15.4% | NV-387 received US FDA Orphan Drug Designation for measles. |
| Apr 21 | Disease context update | Positive | -1.6% | Company highlighted measles outbreaks and positioned NV-387 as candidate treatment. |
| Apr 07 | RPDD application | Positive | +6.9% | Filed Rare Pediatric Disease Drug designation application for NV-387 in measles. |
| Apr 01 | Phase II trial plan | Positive | +4.7% | Announced upcoming Phase II clinical trial of NV-387 for MPox. |
| Mar 11 | Conference & manufacturing | Positive | +18.3% | Investor conference participation and completion of Phase II NV-387 oral gummies manufacture. |
24h Move is the share-price change in the day after each event; other market factors may also have contributed.
Recent clinically focused and designation-related updates for NV-387 often saw positive price reactions, though not uniformly.
Over recent months, NNVC news has centered on its antiviral NV-387 and capital markets activity. On May 4, 2026, Orphan Drug Designation for measles drove a 15.38% gain. Earlier measles-related communications on April 21 saw a modest -1.56% move, while a Rare Pediatric Disease application on April 7 corresponded to a 6.93% rise. Phase II plans for MPox on April 1 and a March investor conference plus Phase II product readiness on March 11 led to gains of 4.66% and 18.32%, respectively. Today’s routine conference participation fits this ongoing investor-relations cadence.
AI-generated analysis. How Rhea-AI works. Not financial advice.
Shelton, Connecticut--(Newsfile Corp. - May 6, 2026) - NanoViricides, Inc. (NYSE American: NNVC), today announced its participation in the D. Boral Capital Global Conference, taking place May 7, 2026, at The Plaza Hotel in New York City.
Anil R. Diwan, PhD, President & Exec. Chairman will be hosting one-on-one meetings on May 7th from 9:45 A.M. to 2:45 P.M. (ET).
To register for one-on-one meetings with management at The Plaza Hotel in New York City, interested parties should contact the DBC Conference Team at dbcconferenceteam@dboralcapital.com.
About NanoViricides, Inc.
NanoViricides, Inc., is a publicly traded company (NYSE American: NNVC) (the "Company"), and a clinical stage, leading global pioneer in the development of broad-spectrum antivirals based on host-mimetic nanomedicine technology that viruses and their variants cannot escape. Its clinical stage, broad-spectrum, antiviral drug NV-387 has been granted an “Orphan Drug Designation” (ODD) by the US FDA Office of Orphan Products Development (OOPD). This could lead to could provide 7 years market exclusivity, tax credits for clinical trial costs, and fee exemptions upon approval. NV-387 is a revolutionary antiviral that we believe will be the drug offered at “ first visit” when the patient presents to a doctor with any respiratory viral illness. NV-387 was also found to be highly effective in lethal animal infection models of Influenza, RSV, Coronaviruses, Monkeypox, Smallpox, and Measles.
About D. Boral Capital
D. Boral Capital LLC is a premier, relationship-driven global investment bank headquartered in New York. The firm is dedicated to delivering exceptional strategic advisory and tailored financial solutions to middle-market and emerging growth companies. With a proven track record, D. Boral Capital provides expert guidance to clients across diverse sectors worldwide, leveraging access to capital from key markets, including the United States, Asia, Europe, the Middle East, and Latin America.
A recognized leader on Wall Street, D. Boral Capital has successfully aggregated approximately
For further information:
Meeta R Vyas
CFO
+1 (203) 937-6137
info@nanoviricides.com
www.nanoviricides.com
Source NanoViricides, Inc.